SNX0723

• CAT Number: I036458
• CAS Number: 1073969-18-2
• Molecular Formula: C22H26FN3O3
• Molecular Weight: 399.47
• Purity: 98%
• Synonyms: SNX0723; SNX 0723; SNX- 0723.
• Solubility: Soluble in DMSO
• Appearance: Solid powder
• Storage: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
• IUPAC Name: 2-fluoro-6-[[(3S)-oxolan-3-yl]amino]-4-(3,6,6-trimethyl-4-oxo-5,7-dihydroindol-1-yl)benzamide
• InChI: InChI=1S/C22H26FN3O3/c1-12-10-26(17-8-22(2,3)9-18(27)19(12)17)14-6-15(23)20(21(24)28)16(7-14)25-13-4-5-29-11-13/h6-7,10,13,25H,4-5,8-9,11H2,1-3H3,(H2,24,28)/t13-/m0/s1
• InChIKey: GAGDTKJJVCLACJ-ZDUSSCGKSA-N
• SMILES: CC1=CN(C2=C1C(=O)CC(C2)(C)C)C3=CC(=C(C(=C3)F)C(=O)N)N[C@H]4CCOC4

SNX0723（Cat No.:I036458）is a selective inhibitor of the protein kinase CK2, which is implicated in various cellular processes, including cell growth, proliferation, and survival. By targeting CK2, SNX0723 disrupts its enzymatic activity, leading to altered signaling pathways that can promote apoptosis in cancer cells. This compound has shown promise in preclinical studies for its potential efficacy against a range of malignancies, including those resistant to conventional therapies. Ongoing research aims to evaluate its therapeutic applications and safety profile, positioning SNX0723 as a potential candidate for targeted cancer treatments in future clinical settings.

Reference

1. Putcha P, Danzer KM, Kranich LR, Scott A, Silinski M, Mabbett S, Hicks CD, Veal JM, Steed PM, Hyman BT et al.. (2010) Brain-permeable small-molecule inhibitors of Hsp90 prevent alpha-synuclein oligomer formation and rescue alpha-synuclein-induced toxicity. J. Pharmacol. Exp. Ther., 332 (3): 849-57. [PMID:19934398]